Hematopoietic Biology & Malignancy

The Hematopoietic Biology and Malignancy Department (HBM) aims to implement broad-based efforts aimed at better understanding the underlying biology of hematological malignancies with the ultimate goal of developing new therapies to treat these maladies. Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes. This classification of cancers includes leukemia, lymphoma and myeloma. In order to address the challenges of these deadly diseases, this basic research science department brings together scientists, physician-scientists, researchers and trainees with the vision, talent and expertise needed to pursue the goal of curing these diseases.

MD Anderson is a recognized leader in cancer research. In addition to MD Anderson’s team of highly accomplished faculty and researchers, the institution enjoys incredible support via outstanding core facilities which help to initiate, enable and accelerate discoveries. These include, but are not limited to, state of the art flow cytometry and cell sorting capabilities, functional genomics, proteomics, and metabolomics, advanced microscopy, histology and immunohistochemistry and biostatistics. The availability of these key resources along with the capacity for collaboration among scientists and physicians in other clinical, basic and translational departments provide HBM with an unparalleled opportunity to tackle the pressing questions and address the unmet challenges of developing cures for hematopoietic cancers.

In order to make the most of this exceptional opportunity, the department is committed to recruiting the top talent and collaborating with the top scientists across MD Anderson and externally and bringing much-needed, novel treatments to patients.